慢性肾病患者的血清肿瘤标志物

Serum tumour markers in patients with chronic kidney disease.

作者信息

Xiaofang Y, Yue Z, Xialian X, Zhibin Y

机构信息

Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China.

出版信息

Scand J Clin Lab Invest. 2007;67(6):661-7. doi: 10.1080/00365510701282326.

DOI:10.1080/00365510701282326

PMID:17852811

Abstract

UNLABELLED

OBJECTIVE. Tumour markers are widely used for monitoring cancer patients and for screening certain tumours. It has recently been shown that the concentrations of some tumour markers are higher in patients with chronic kidney disease (CKD) than in healthy subjects. We analysed the influence of renal function and hemodialysis treatment on the serum levels of CA19-9, CA125, alpha fetoprotein (AFP), CA15.3, CA72.4, CYFRA 21-1, neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC-Ag).

MATERIAL AND METHODS

232 non-dialysis patients with CKD and 37 uraemic patients treated with maintenance hemodialysis were enrolled in this study. The nondialysis patients were divided into three groups depending on their creatinine clearance (Ccr) levels: group 1 = Ccr < or =25 mL/min; group 2 = 25.1-49.9 mL/min; group 3 = Ccr > or =50 mL/min. For comparison, we chose 37 non-dialysis patients with similar Ccr, age and same gender as controls.

RESULTS

The serum concentrations of CA19-9, CA125 (male), CYFRA 21-1, NSE and SCC-Ag correlated negatively with Ccr, while there were no significant differences in the concentrations of CA125 (female), AFP, CA15.3, CA72.4. The serum levels of CA19-9, CA125, AFP, CA15.3, CA72.4, CYFRA 21-1, NSE and SCC-Ag showed no differences between hemodialysis patients and non-dialysis controls (p > 0.017).

CONCLUSIONS

The increase in the serum levels of CA19-9, CA125 (in males), CYFRA 21-1, NSE and SCC-Ag in patients with CKD affects the specificity of these markers in the diagnosis of cancer. Hemodialysis does not affect the serum levels of CA19-9, CA125, AFP, CA15.3, CA72.4, CYFRA 21-1, NSE and SCC-Ag.

摘要

未标注

目的。肿瘤标志物广泛用于监测癌症患者以及筛查某些肿瘤。最近有研究表明，慢性肾脏病（CKD）患者体内某些肿瘤标志物的浓度高于健康受试者。我们分析了肾功能及血液透析治疗对血清CA19-9、CA125、甲胎蛋白（AFP）、CA15.3、CA72.4、细胞角蛋白19片段（CYFRA 21-1）、神经元特异性烯醇化酶（NSE）和鳞状细胞癌抗原（SCC-Ag）水平的影响。

材料与方法

本研究纳入了232例非透析CKD患者和37例接受维持性血液透析的尿毒症患者。非透析患者根据其肌酐清除率（Ccr）水平分为三组：1组 = Ccr≤25 mL/分钟；2组 = 25.1 - 49.9 mL/分钟；3组 = Ccr≥50 mL/分钟。为作比较，我们选取了37例Ccr、年龄和性别与之相似的非透析患者作为对照。

结果

血清CA19-9、CA125（男性）、CYFRA 21-1、NSE和SCC-Ag浓度与Ccr呈负相关，而CA125（女性）、AFP、CA15.3、CA72.4浓度无显著差异。血液透析患者与非透析对照之间血清CA19-9、CA125、AFP、CA15.3、CA72.4、CYFRA 21-1、NSE和SCC-Ag水平无差异（p > 0.017）。